drugset / Trial / NCT06167707

Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers

NCT06167707

Phase 1 Completed 21 enrolled scPharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to compare the pharmacokinetics and pharmacodynamics of subcutaneous (SC) and intravenous (IV) furosemide. The test formulation in this study is furosemide injection, 80 mg/1 mL, buffered to a neutral pH for SC administration via an autoinjector. A commercial formulation of furosemide injection, USP, solution 10 mg/mL administered as a 40 mg IV injection over 2 minutes followed by a second dose of 40 mg, 2 hours later, will serve as the reference drug. The objectives of this study are: * To estimate the bioavailability and describe the pharmacokinetics and pharmacodynamics of furosemide administered as SC injection via autoinjector compared with equivalent dose of furosemide administered as two 40 mg IV injections, two hours apart. * To describe the safety and tolerability of furosemide administered as SC injection via an autoinjector.

Timeline

Start
2024-04-19
Primary completion
2024-06-14
Completion
2024-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 40 mg Subcutaneous
Subject Furosemide Other / unclassified 80 mg Subcutaneous

Indications